BIOLOG-ID
27.9.2021 15:29:05 CEST | Business Wire | Press release
Biolog-id, a global service provider of connected healthcare solutions, and Fujicom, a national distributor of high-quality medical-hospital products and services, get into a partnership to offer Biolog Transfusion Solution on the Brazilian market.
With more than 40 years of experience in the healthcare sector, Fujicom is a leading supplier in the market by providing high technology medical equipment. Throughout Brazil, the company provides more than 500 customers such as blood centers, public and private blood banks, hospitals and clinics with breakthrough and innovative products.
Flexible and reliable, Biolog Transfusion Solution combines software, equipment and RFID tags offering a comprehensive solution for blood components traceability, from the collection to the hospital blood banks. Divided into several modules (Processing, Inventory and Transport) addressing each application area of the transfusion supply chain, this solution optimizes the management of the lifesaving medical resources while enhancing operational efficiency.
“Due to its core business and its well-recognized experience, Fujicom is without a doubt a key player on the Brazilian transfusion market. We are very pleased to cooperate with them.” explains Philippe Jacquet, Executive Director of Sales EMEA/LATAM at biolog-id. “Several opportunities have already been identified and we are confident that during the coming months, Fujicom will manage those toward a positive conclusion and implementation”.
“The arrival of biolog-id’s innovative solution on the Brazilian blood bank market will foster the improvement of the traceability and control of processes that remain non-automated yet” underlines Sandra Fujita, Commercial Director at Fujicom. “Based on RFID technology, it will ensure our clients a more efficient management of their product inventory by improving the profitability and the quality of the services provided.”
As previously announced, biolog-id and Fujicom will rely on the expertise of SBS Consultores system - a leading Brazilian software company well established in the transfusion sector – to integrate and implement Biolog Transfusion Solution while providing on-site support.
About biolog-id
:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds. Xerys Invest is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About Fujicom:
Fujicom, one of the Fujita Group companies with more than 40 years of presence in the healthcare field, operates throughout Brazil in the commercialization of premium medical-hospital technologies, products, solutions and services.
With its headquarters in Fortaleza and branches in São Paulo and Paraíba, in addition to representatives throughout the country, Fujicom serves more than 500 customers throughout the country, such as blood centers, public and private blood banks, hospitals and clinics.
In Brazil, it has exclusive partnerships with international manufacturers that constantly invest in the development of technologies for their products and share the same goal: Excellence and Innovation.
Company URL: www.fujicom.com.br
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005515/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Modon's Hudayriyat Golf Estates Sets UAE Record With More Than AED 13 Billion in Sales Within Days of Launch7.7.2026 20:36:00 CEST | Press release
A record-breaking sales value for a residential project in the UAEThe project comprises golf mansions, villas, and townhouses across Hudayriyat Island, Abu Dhabi1,700 residences sold within days after the launch15% non-UAE resident buyers81% new customers to Modon Modon has set a new benchmark for the UAE real estate market with the launch of Hudayriyat Golf Estates on Hudayriyat Island, Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707126559/en/ Modon's Hudayriyat Golf Estates sets UAE record with more than AED 13 billion in sales within days of launch (Photo: AETOSWire) Within days of launch, the community achieved record-breaking sales exceeding AED 13 billion, marking the highest publicly recorded sales value for a single residential project launch in the UAE. Comprising an exclusive collection of golf mansions, villas, and townhouses, the development saw 1,700 of its residences sold after few days of laun
Loomis Sayles Growth Equity Strategies Team Celebrates Twenty-Year Milestones7.7.2026 16:36:00 CEST | Press release
Loomis, Sayles & Company, the century-old investment manager with nearly $418 billion in assets under management, proudly celebrates the 20-year anniversaries of the Loomis Sayles Large Cap Growth and the Loomis Sayles All Cap Growth strategies, as well as a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707992418/en/ Celebrating 20 Years of The Power of Active Management Done Right GES is a cohesive team with 20 years of alpha generation and a long-term, private equity approach to investing. Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to $98.2 billion
Integral Ad Science Appoints Lidiane Jones Chief Executive Officer7.7.2026 15:35:00 CEST | Press release
Accomplished AI and technology executive to lead IAS's next phase of innovation and growth; Lisa Utzschneider to serve as Special Advisor to the Board through year-end Integral Ad Science (IAS), one of the world's most trusted media quality companies, today announced the appointment of Lidiane Jones as Chief Executive Officer, effective immediately. Jones succeeds Lisa Utzschneider, who led IAS for more than seven years and will remain with the company as Special Advisor to the Board through the end of 2026 to support a seamless transition. Utzschneider will also serve as a Special Advisor to Novacap and their portfolio companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707780892/en/ Lidiane Jones: Integral Ad Science CEO, Photo Credit: Pamela Hanson The appointment reflects IAS's long-term strategic vision for the future of digital advertising. As AI transforms how media is planned, bought, measured, and optimized
Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough7.7.2026 15:00:00 CEST | Press release
Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in accelerating drug development timelines. Building on proven results in clinical reporting, where the collaboration has achieved up to first-draft clinical study reports (CSRs), the teams have now successfully applied similar AI capabilities to nonclinical data through high-quality parsing of raw and SEND datasets in a proof-of-concept. This advancement aligns with the Altasciences Acceleration Platform, designed to fast-track drug development across the early-phase development continuum. “This milestone reflects the power of in
SS&C Expands Tokenized Investment Capabilities with Digital Cash Settlement7.7.2026 15:00:00 CEST | Press release
Building on live tokenized fund issuance and distribution capabilities, SS&C extends its innovation roadmap to support the next stage of digital investment markets SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced plans to enable digital cash settlement for tokenized investment transactions using regulated forms of digital cash, including stablecoins and tokenized commercial bank deposits. The announcement builds on the successful launch of SS&C's live tokenized fund issuance and distribution capabilities earlier this year following the acquisition of Calastone in 2025. SS&C already enables asset managers to bring tokenized versions of traditional investment funds to market through the infrastructure and connectivity they already use, helping bridge traditional and digital investment markets. As interest in tokenized investment products continues to grow, the market is increasingly looking beyond tokenization towards the infrastructure needed to support digital transactio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom